Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Completes Public Offering, Raises $2.7M

NEW YORK (GenomeWeb) – Precipio announced after the close of the market on Monday the completion of its public offering of securities that raised $2.7 million in gross proceeds.

The company completed its direct offering of 2,748 units, each unit comprising one share of Series C preferred stock, convertible at $1.40 per share, and warrants to purchase up to 1,962.857 shares of common stock at an exercise price of $1.63 per share.

The offering was a follow-on to a previous capital raise during the summer that brought in $6 million. In a statement, Precipio President and CEO Ilan Danieli said that while the initial financing helped jumpstart the firm, "we required more capital to execute on our business plan. We believe this new financing enables us to make significant investments in the R&D and sales and marketing aspects of the business."

Aegis Capital was the sole placement agent for the most recent offering. 

Precipio Diagnostics merged with Transgenomic in June and the combined company adopted the Precipio name. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.